Company Profile

IDEAYA Biosciences Stock Price, News & Catalysts

Ticker:
IDYA
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

26.17 USD (-1.21%)

Close

Last updated: November 19, 2026

2.45B USD

Market cap

Why the stock is moving

As of Nov 19, 2026, IDYA closed down 1.21% at $26.17. No new same-company headline was identified in the current news window.

Company overview

Precision Oncology Portfolio

IDEAYA Biosciences develops targeted oncology therapies using synthetic lethality and biomarker-defined patient selection. Its portfolio combines a late-stage uveal melanoma franchise with antibody-drug conjugates and small molecules directed at genetically defined cancers.

Darovasertib in Metastatic Uveal Melanoma

Darovasertib is a protein kinase C inhibitor being developed with crizotinib. The Phase 2/3 OptimUM-02 trial met its primary endpoint in first-line HLA-A2-negative metastatic uveal melanoma and supports a planned accelerated-approval NDA.

Broader Uveal Melanoma Development

OptimUM-01 evaluates the darovasertib combination in HLA-A2-positive metastatic disease, while OptimUM-09 studies neoadjuvant treatment in primary uveal melanoma. IDEAYA is also planning the Phase 3 OptimUM-11 trial in the adjuvant setting.

ADC Pipeline

IDE849 is a DLL3-targeted topoisomerase-1 antibody-drug conjugate in Phase 1/2 development, with a registrational monotherapy trial planned in DLL3-positive tumors. IDE034 is a bispecific B7H3 and PTK7 topoisomerase-1 ADC in early clinical development.

Synthetic-Lethality Combinations

IDE397 inhibits MAT2A in MTAP-deleted tumors, while IDE892 targets PRMT5. A planned combination cohort will test dual suppression of the methylthioadenosine pathway in biomarker-selected cancers.

Future catalysts

  • Initial IDE849 data from the global Phase 1/2 study by year-end 2026 or early 2027.
  • Initiation of two registrational Phase 3 IDE849 trials by year-end 2026.
  • Initiation of the IDE892-plus-RG6505 Phase 1 combination study by year-end 2026.
  • Initial Phase 1 IDE034 data in 2027.

Recent news

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What is the current stock price of IDEAYA Biosciences (IDYA)?

IDEAYA Biosciences (IDYA) most recently closed at 26.17 USD, a -1.21% move versus the previous session.

What is the market cap of IDEAYA Biosciences (IDYA)?

IDEAYA Biosciences currently has a market capitalization of 2.45B USD on BioPharmSignal.

What does IDEAYA Biosciences do?

Precision Oncology Portfolio IDEAYA Biosciences develops targeted oncology therapies using synthetic lethality and biomarker-defined patient selection. Its portfolio combines a late-stage uveal melanoma franchise with antibody-drug conjugates and small molecules directed at genetically defined cancers. Darovasertib in Metastatic Uveal Melanoma Darovasertib...

On which exchange is IDYA stock listed?

IDEAYA Biosciences (IDYA) is associated with NASDAQ, United States, Biopharma.

What is HLA-A2?

The Phase 2/3 OptimUM-02 trial met its primary endpoint in first-line HLA-A2-negative metastatic uveal melanoma and supports a planned accelerated-approval NDA.

Which conditions is IDEAYA Biosciences targeting with HLA-A2?

IDEAYA Biosciences is associated with oncology, cancer therapeutics, genetic disease based on its company overview and current catalyst commentary.

How does IDEAYA Biosciences describe recent progress with HLA-A2?

Initial IDE849 data from the global Phase 1/2 study by year-end 2026 or early 2027. Initiation of two registrational Phase 3 IDE849 trials by year-end 2026. Initiation of the IDE892-plus-RG6505 Phase 1 combination study by year-end 2026. Initial Phase 1 IDE034 data in 2027.

What is crizotinib?

Darovasertib in Metastatic Uveal Melanoma Darovasertib is a protein kinase C inhibitor being developed with crizotinib.